Mingot, M. E., Carpenedo, M., Hinryk, M. C., Trelles, R., Ureña, L. E., Porras, J. R. G., Izquierdo, M. C. P., Castillo, M. C. G. D., Cortina, P. R., Santoro, C., Stefano, V. D., Artoni, A., Vianelli, N., Clark, J., Clavel, J., González, B. S., Desborough, M., Bagot, C., Valcárcel, D., Román, M. T. Ã., Almela, M. L. L., Lowe, G., Fernandez, C. R., Jorge, S. J., Acosta, M. A. L., Thomas, I., Smith, J., Bradbury, C. (2025). A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study. Blood. https://doi.org/10.1182/blood-2025-733